Rosetta Genomics Says ‘Technical Obstacles’ Will Delay Colorectal Cancer Screen Launch | GenomeWeb

By Doug Macron

Rosetta Genomics this week announced that it has pushed back the expected launch date for its blood-based colorectal cancer screen until the middle of next year as it addresses inconsistencies observed in measuring the microRNA biomarkers used in the test.

The company also said that CEO Amir Avniel intends to step down from his position at the company in order to take the reins of Rosetta’s roughly year-old plant biotechnology unit, Rosetta Green.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.